EIBALL Session - Jointly organised with the Quantitative Medical Imaging Coalition (QMIC)

EIBALL 12 - Quantitative imaging in metabolic dysfunction-associated steatohepatitis (MASH)

March 6, 08:00 - 09:00 CET

5 min
Chairpersons' introduction
15 min
Quantitative imaging biomarkers in MASH: from concept to clinical criteria
  1. To learn the principles behind quantitative imaging biomarkers and their potential role in assessing MASH.
  2. To appreciate how imaging biomarkers can support diagnostic confidence and clinical decision-making in MASH.
  3. To understand the criteria and challenges for validating imaging biomarkers as surrogate endpoints in clinical trials and routine care.
15 min
Monitoring MASH progression and treatment response with quantitative imaging
  1. To learn about imaging techniques currently used to quantify liver fat, inflammation, and fibrosis in MASH.
  2. To appreciate the strengths and limitations of quantitative imaging for monitoring disease evolution and therapeutic response.
  3. To understand how imaging biomarkers can complement or replace biopsy in longitudinal assessment of MASH.
15 min
Quality, standardisation, and best practices in quantitative ultrasound imaging for MASH
  1. To learn the importance of quality assurance and quality control (QA/QC) in quantitative liver imaging.
  2. To appreciate the parallels between standardisation in imaging and laboratory-based diagnostics.
  3. To understand current initiatives and frameworks for ensuring reproducibility and cross-centre consistency in quantitative imaging measurements.
10 min
Panel discussion: What are the barriers to implementing quantitative imaging in MASH?